FDA Proposes Removing GLP-1s from 503B Bulks List: What Patients Need to Know
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Public comments close June 29. Here's what patients and providers need to understand.
Proposal: Exclude semaglutide, tirzepatide, liraglutide from 503B compounding
Reason: FDA says no current clinical need — branded versions are available
Comment deadline: June 29, 2026
Impact: 503B outsourcing facilities; 503A pharmacies under separate rules
Understanding the 503B Bulks List
The 503B Bulks List identifies bulk drug substances that FDA-registered outsourcing facilities can use in compounding. Being on this list is what allowed large-scale compounders to produce semaglutide and tirzepatide at volume during the 2022-2024 drug shortages.
When the FDA resolved the semaglutide shortage in February 2025 and the tirzepatide shortage in late 2024, the legal basis for compounding under shortage provisions ended. The 503B Bulks List was the remaining pathway for outsourcing facilities — and the FDA now wants to close it.
The FDA's Reasoning
The proposal is built on three regulatory pillars:
1. No Clinical Need
The FDA's position is that FDA-approved versions of all three drugs (Wegovy/Ozempic, Zepbound/Mounjaro, Saxenda/Victoza) are commercially available in sufficient supply. The agency argues there's no clinical justification for outsourcing facilities to compound from bulk substances.
2. Safety Signal Data
By early 2025, the FDA had received over 455 adverse event reports for compounded semaglutide and 320+ for compounded tirzepatide. Many involved dosing errors from patients self-administering from multi-dose vials — some requiring hospitalization.
3. Quality Concerns
Independent testing of some compounded products allegedly revealed impurity levels as high as 86%, according to litigation filed by Novo Nordisk. The FDA has also flagged concerns about counterfeit products entering the market through online channels.
503B vs. 503A: The Critical Distinction
This proposal specifically targets 503B outsourcing facilities. The regulatory framework for 503A traditional compounding pharmacies operates under separate authority:
| 503B Outsourcing Facility | 503A Traditional Pharmacy | |
|---|---|---|
| Scale | Large-scale, without individual prescriptions | Patient-specific prescriptions only |
| Oversight | FDA-registered, subject to cGMP | State pharmacy board regulated |
| This proposal | Directly affected | Not directly targeted |
| Typical providers | Large telehealth platforms | Traditional compounding pharmacies |
Many telehealth providers work with 503A state-licensed pharmacies, which compound based on valid, patient-specific prescriptions. This proposal doesn't directly eliminate that pathway, though the FDA has signaled broader enforcement intent.
Oak Longevity · $130/mo sema
Compare Current Provider Options →Compounded medications are not FDA-approved. Paid link
The Pricing Reality
The core tension driving this debate is cost. Compounded GLP-1 medications typically cost $130-$300/month. Brand-name alternatives remain significantly more expensive for most patients:
| Option | Monthly Cost (Self-Pay) | Status |
|---|---|---|
| Compounded semaglutide | $130-$300 | Currently available through 503A/503B |
| Oral Wegovy (brand) | $149 | Available since Jan 2026 |
| Wegovy injection (brand) | $349+ after intro period | Available |
| Zepbound injection (brand) | $550+ | Available (with savings programs) |
Novo Nordisk's decision to price the oral Wegovy pill at $149/month is widely seen as a strategic response to compounding competition. Whether this price point is sustainable long-term remains to be seen.
Affordable Options Today
$130/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
$146/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
$179/mo flat
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
Timeline and What to Expect
- Now through June 29, 2026: Public comment period is open — patients, providers, and industry can submit input
- Post-comment review: FDA evaluates all submissions (typically 3-6 months)
- Final rule publication: Could come late 2026 or early 2027
- Compliance period: Facilities would have time to wind down operations after final rule
Based on standard FDA rulemaking timelines, compounded GLP-1 access through various channels is expected to continue through at least late 2026 and potentially into 2027.
What Patients Should Do
- Ask your provider about pharmacy type. Know whether your medication comes from a 503A or 503B facility.
- Don't stockpile. Compounded medications have expiration dates and storage requirements.
- Explore brand-name alternatives. Oral Wegovy at $149/month and manufacturer savings programs have significantly narrowed the price gap.
- Stay current. Regulatory changes in this space are moving fast — what's true today may shift within weeks.
Sesame Care · brand-name Rx
Explore Brand-Name Options →Prescribes FDA-approved brand-name medications. Paid link
The Bottom Line
The FDA's 503B Bulks List proposal is the most significant regulatory action against compounded GLP-1s to date, but it's not an immediate shutdown. The rulemaking process takes months, 503A pharmacies operate under different rules, and brand-name alternatives are becoming more affordable. Patients with active prescriptions should continue treatment while staying informed about their specific provider's regulatory pathway.
Sources
- FDA proposed rule, Federal Register, May 2026 — 503B Bulks List exclusion
- Pharmacy Times, "FDA Moves to Permanently Close the Door on Compounded GLP-1s," May 13, 2026
- Medical News Today, "FDA moves to remove GLP-1 medications from 503B Bulks List," May 2026
- FDA adverse event reporting data, compounded semaglutide and tirzepatide, early 2025